Growth Metrics

Gyre Therapeutics (GYRE) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Gyre Therapeutics (GYRE) over the last 12 years, with Q3 2025 value amounting to $483000.0.

  • Gyre Therapeutics' Change in Account Payables rose 162500.0% to $483000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $256000.0, marking a year-over-year increase of 26100.63%. This contributed to the annual value of -$245000.0 for FY2024, which is 15764.71% down from last year.
  • Per Gyre Therapeutics' latest filing, its Change in Account Payables stood at $483000.0 for Q3 2025, which was up 162500.0% from -$51000.0 recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Change in Account Payables peaked at $6.3 million during Q4 2022, and registered a low of -$3.7 million during Q2 2022.
  • Over the past 5 years, Gyre Therapeutics' median Change in Account Payables value was -$23000.0 (recorded in 2024), while the average stood at $53368.4.
  • As far as peak fluctuations go, Gyre Therapeutics' Change in Account Payables tumbled by 71311.48% in 2021, and later surged by 162500.0% in 2025.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Change in Account Payables stood at $2.6 million in 2021, then surged by 144.48% to $6.3 million in 2022, then plummeted by 101.66% to -$104000.0 in 2023, then tumbled by 82.69% to -$190000.0 in 2024, then surged by 354.21% to $483000.0 in 2025.
  • Its Change in Account Payables stands at $483000.0 for Q3 2025, versus -$51000.0 for Q2 2025 and $14000.0 for Q1 2025.